CDK12 Inhibition

CI-VAR-00002060Explore in graph →CIViC 5251

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease1unmapped disease
CDK12 Inhibition	(functional)	Functional	D	Supports Loss Of Function	2	submitted	EID12570 In BRAF-mutated melanoma cell lines (A375, WM983A/B, WM164, Colo829), the selective CDK12/13 inhibitor SR-4835 inhibited proliferation (IC₅₀ = 80.7–160.5 nM) and at 30/100nM, reduced RNA polymerase II… (full text at CIViC) PMID 38104154 · Houles et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.